Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells - PubMed (original) (raw)
. 1991 May 15;51(10):2521-3.
Affiliations
- PMID: 1708695
Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells
T Terachi et al. Cancer Res. 1991.
Abstract
Autologous immunoglobulin was detected on the cell surface of tumor cells freshly isolated from cancerous kidneys of patients with renal cell carcinoma by flow cytometry after staining with murine anti-human IgG monoclonal antibodies. Cells isolated in parallel from macroscopically normal regions of the tumorous kidneys were not specifically stained with the anti-human IgG reagents. In further studies, tumor cells were stained with an antibody to decay-accelerating factor (DAF), a known inhibitor of complement. Flow cytometry of these cells revealed that nearly all tumor cells expressed DAF, and that the intensity of staining with the anti-DAF monoclonal antibody correlated with the staining of cells with anti-IgG. The results suggest that tumor cells coated with autologous antibody may be resistant to complement-mediated cytotoxicity in vivo through the expression of high levels of DAF.
Similar articles
- Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Niehans GA, et al. Am J Pathol. 1996 Jul;149(1):129-42. Am J Pathol. 1996. PMID: 8686736 Free PMC article. - Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ. Gorter A, et al. Lab Invest. 1996 Jun;74(6):1039-49. Lab Invest. 1996. PMID: 8667608 - Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland.
Lass JH, Walter EI, Burris TE, Grossniklaus HE, Roat MI, Skelnik DL, Needham L, Singer M, Medof ME. Lass JH, et al. Invest Ophthalmol Vis Sci. 1990 Jun;31(6):1136-48. Invest Ophthalmol Vis Sci. 1990. PMID: 1693916 - Comparative studies of decay-accelerating factor and HLA-DR within the CD8-brightly positive population.
Tomita A, Okada N, Okada H. Tomita A, et al. Eur J Immunol. 1991 Aug;21(8):1843-8. doi: 10.1002/eji.1830210810. Eur J Immunol. 1991. PMID: 1714392 - Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B, Ma ZW, Li H, Xu GL, Zheng P, Zhu B, Wu YZ, Zou Q. Guo B, et al. Clin Immunol. 2008 Aug;128(2):155-63. doi: 10.1016/j.clim.2008.03.507. Epub 2008 May 23. Clin Immunol. 2008. PMID: 18502181
Cited by
- Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
Fishelson Z, Kirschfink M. Fishelson Z, et al. Front Immunol. 2019 Apr 10;10:752. doi: 10.3389/fimmu.2019.00752. eCollection 2019. Front Immunol. 2019. PMID: 31024572 Free PMC article. Review. - Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
Ramajayam R, Tan KP, Liu HG, Liang PH. Ramajayam R, et al. Bioorg Med Chem. 2010 Nov 15;18(22):7849-54. doi: 10.1016/j.bmc.2010.09.050. Epub 2010 Sep 25. Bioorg Med Chem. 2010. PMID: 20947359 Free PMC article. - Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
Qian YM, Haino M, Kelly K, Song WC. Qian YM, et al. Immunology. 1999 Oct;98(2):303-11. doi: 10.1046/j.1365-2567.1999.00859.x. Immunology. 1999. PMID: 10540231 Free PMC article. - Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Niehans GA, et al. Am J Pathol. 1996 Jul;149(1):129-42. Am J Pathol. 1996. PMID: 8686736 Free PMC article. - Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.
Baranyi L, Baranji K, Takizawa H, Okada N, Okada H. Baranyi L, et al. Immunology. 1994 Aug;82(4):522-8. Immunology. 1994. PMID: 7835914 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous